Literature DB >> 21369831

Development and evaluation of a decision aid for BRCA carriers with breast cancer.

Julie O Culver1, Deborah J MacDonald, Andrea A Thornton, Sharon R Sand, Marcia Grant, Deborah J Bowen, Harry Burke, Nellie Garcia, Kelly A Metcalfe, Jeffrey N Weitzel.   

Abstract

BRCA+ breast cancer patients face high risk for a second breast cancer and ovarian cancer. Helping these women decide among risk-reducing options requires effectively conveying complex, emotionally-laden, information. To support their decision-making needs, we developed a web-based decision aid (DA) as an adjunct to genetic counseling. Phase 1 used focus groups to determine decision-making needs. These findings and the Ottawa Decision Support Framework guided the DA development. Phase 2 involved nine focus groups of four stakeholder types (BRCA+ breast cancer patients, breast cancer advocates, and genetics and oncology professionals) to evaluate the DA's decision-making utility, information content, visual display, and implementation. Overall, feedback was very favorable about the DA, especially a values and preferences ranking-exercise and an output page displaying personalized responses. Stakeholders were divided as to whether the DA should be offered at-home versus only in a clinical setting. This well-received DA will be further tested to determine accessibility and effectiveness.

Entities:  

Mesh:

Year:  2011        PMID: 21369831      PMCID: PMC3531556          DOI: 10.1007/s10897-011-9350-4

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  53 in total

Review 1.  Decision aids for patients considering options affecting cancer outcomes: evidence of efficacy and policy implications.

Authors:  A M O'Connor; V Fiset; C DeGrasse; I D Graham; W Evans; D Stacey; A Laupacis; P Tugwell
Journal:  J Natl Cancer Inst Monogr       Date:  1999

2.  Surveillance or surgery? A description of the factors that influence high risk premenopausal women's decisions about prophylactic oophorectomy.

Authors:  N Hallowell; I Jacobs; M Richards; J Mackay; M Gore
Journal:  J Med Genet       Date:  2001-10       Impact factor: 6.318

3.  Concerns of women presenting to a comprehensive cancer centre for genetic cancer risk assessment.

Authors:  D J MacDonald; J Choi; B Ferrell; S Sand; S McCaffrey; K R Blazer; M Grant; J N Weitzel
Journal:  J Med Genet       Date:  2002-07       Impact factor: 6.318

4.  Longitudinal changes in patient distress following interactive decision aid use among BRCA1/2 carriers: a randomized trial.

Authors:  Gillian W Hooker; Kara-Grace Leventhal; Tiffani DeMarco; Beth N Peshkin; Clinton Finch; Erica Wahl; Jessica Rispoli Joines; Karen Brown; Heiddis Valdimarsdottir; Marc D Schwartz
Journal:  Med Decis Making       Date:  2010-09-27       Impact factor: 2.583

5.  Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.

Authors:  M C King; S Wieand; K Hale; M Lee; T Walsh; K Owens; J Tait; L Ford; B K Dunn; J Costantino; L Wickerham; N Wolmark; B Fisher
Journal:  JAMA       Date:  2001-11-14       Impact factor: 56.272

6.  Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.

Authors:  S A Narod; J S Brunet; P Ghadirian; M Robson; K Heimdal; S L Neuhausen; D Stoppa-Lyonnet; C Lerman; B Pasini; P de los Rios; B Weber; H Lynch
Journal:  Lancet       Date:  2000-12-02       Impact factor: 79.321

7.  Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer.

Authors:  S K McDonnell; D J Schaid; J L Myers; C S Grant; J H Donohue; J E Woods; M H Frost; J L Johnson; D L Sitta; J M Slezak; T B Crotty; R B Jenkins; T A Sellers; L C Hartmann
Journal:  J Clin Oncol       Date:  2001-10-01       Impact factor: 44.544

8.  Understanding the experience of prophylactic bilateral mastectomy: a qualitative study of ten women.

Authors:  S M Lloyd; M Watson; G Oaker; N Sacks; U Querci della Rovere; G Gui
Journal:  Psychooncology       Date:  2000 Nov-Dec       Impact factor: 3.894

9.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

Authors:  Noah D Kauff; Jaya M Satagopan; Mark E Robson; Lauren Scheuer; Martee Hensley; Clifford A Hudis; Nathan A Ellis; Jeff Boyd; Patrick I Borgen; Richard R Barakat; Larry Norton; Mercedes Castiel; Khedoudja Nafa; Kenneth Offit
Journal:  N Engl J Med       Date:  2002-05-20       Impact factor: 91.245

10.  Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.

Authors:  Timothy R Rebbeck; Henry T Lynch; Susan L Neuhausen; Steven A Narod; Laura Van't Veer; Judy E Garber; Gareth Evans; Claudine Isaacs; Mary B Daly; Ellen Matloff; Olufunmilayo I Olopade; Barbara L Weber
Journal:  N Engl J Med       Date:  2002-05-20       Impact factor: 91.245

View more
  12 in total

1.  Development of Breast Cancer Choices: a decision support tool for young women with breast cancer deciding whether to have genetic testing for BRCA1/2 mutations.

Authors:  Chloe Grimmett; Charlotte Brooks; Alejandra Recio-Saucedo; Anne Armstrong; Ramsey I Cutress; D Gareth Evans; Ellen Copson; Lesley Turner; Bettina Meiser; Claire E Wakefield; Diana Eccles; Claire Foster
Journal:  Support Care Cancer       Date:  2018-06-28       Impact factor: 3.603

Review 2.  Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine.

Authors:  Jeffrey N Weitzel; Kathleen R Blazer; Deborah J MacDonald; Julie O Culver; Kenneth Offit
Journal:  CA Cancer J Clin       Date:  2011-08-19       Impact factor: 508.702

3.  The evolution of personalized cancer genetic counseling in the era of personalized medicine.

Authors:  Hetal S Vig; Catharine Wang
Journal:  Fam Cancer       Date:  2012-09       Impact factor: 2.375

4.  Closing the loop: an interactive action-research conference format for delivering updated medical information while eliciting Latina patient/family experiences and psychosocial needs post-genetic cancer risk assessment.

Authors:  Deborah J Macdonald; Julia Deri; Charité Ricker; Martin A Perez; Raquel Ogaz; Nancy Feldman; Lori A Viveros; Benjamin Paz; Jeffrey N Weitzel; Kathleen R Blazer
Journal:  Fam Cancer       Date:  2012-09       Impact factor: 2.375

Review 5.  Decision aids for cancer survivors' engagement with survivorship care services after primary treatment: a systematic review.

Authors:  Yu Ke; Hanzhang Zhou; Raymond Javan Chan; Alexandre Chan
Journal:  J Cancer Surviv       Date:  2022-07-07       Impact factor: 4.442

6.  Development and Testing of a Decision Aid for Unaffected Women with a BRCA1 or BRCA2 Mutation.

Authors:  Terri Jabaley; Meghan L Underhill-Blazey; Donna L Berry
Journal:  J Cancer Educ       Date:  2020-04       Impact factor: 2.037

7.  Seeking balance: decision support needs of women without cancer and a deleterious BRCA1 or BRCA2 mutation.

Authors:  Meghan L Underhill; Cheryl B Crotser
Journal:  J Genet Couns       Date:  2013-11-22       Impact factor: 2.537

Review 8.  Interventions to improve psychosocial well-being in female BRCA-mutation carriers following risk-reducing surgery.

Authors:  Lisa Jeffers; Joanne Reid; Donna Fitzsimons; Patrick J Morrison; Martin Dempster
Journal:  Cochrane Database Syst Rev       Date:  2019-10-09

9.  Decision aid prototype development for parents considering adenotonsillectomy for their children with sleep disordered breathing.

Authors:  Erin Maguire; Paul Hong; Krista Ritchie; Jeremy Meier; Karen Archibald; Jill Chorney
Journal:  J Otolaryngol Head Neck Surg       Date:  2016-11-04

10.  Development of decision aids for female BRCA1 and BRCA2 mutation carriers in Germany to support preference-sensitive decision-making.

Authors:  Sibylle Kautz-Freimuth; Marcus Redaèlli; Kerstin Rhiem; Andrea Vodermaier; Lisa Krassuski; Kathrin Nicolai; Miriam Schnepper; Violetta Kuboth; Julia Dick; Vera Vennedey; Regina Wiedemann; Rita Schmutzler; Stephanie Stock
Journal:  BMC Med Inform Decis Mak       Date:  2021-06-05       Impact factor: 2.796

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.